Vertex Pharmaceuticals Incorporated (LON:0QZU)

Market Cap	98.37B
Revenue (ttm)	8.80B
Net Income (ttm)	-427.82M
Shares Out	n/a
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	231
Average Volume	5,226
Open	480.63
Previous Close	479.89
Day's Range	479.57 - 485.98
52-Week Range	290.87 - 468.17
Beta	0.41
RSI	65.03
Earnings Date	Feb 6, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underl...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1989
• Employees: 6,100
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QZU

Financial Performance

Financial numbers in USD